• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于915MHz辐射热疗联合放疗诱导癌细胞死亡及免疫表型的体外研究

In Vitro Examinations of Cell Death Induction and the Immune Phenotype of Cancer Cells Following Radiative-Based Hyperthermia with 915 MHz in Combination with Radiotherapy.

作者信息

Hader Michael, Streit Simon, Rosin Andreas, Gerdes Thorsten, Wadepohl Martin, Bekeschus Sander, Fietkau Rainer, Frey Benjamin, Schlücker Eberhard, Gekle Stephan, Gaipl Udo S

机构信息

Department of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany.

Translational Radiobiology, Department of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany.

出版信息

Cells. 2021 Jun 8;10(6):1436. doi: 10.3390/cells10061436.

DOI:10.3390/cells10061436
PMID:34201238
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8230049/
Abstract

Multimodal tumor treatment settings consisting of radiotherapy and immunomodulating agents such as immune checkpoint inhibitors are more and more commonly applied in clinics. In this context, the immune phenotype of tumor cells has a major influence on the anti-tumor immune response as well as the composition of the tumor microenvironment. A promising approach to further boost anti-tumor immune responses is to add hyperthermia (HT), i.e., heating the tumor tissue between 39 °C to 45 °C for 60 min. One key technique is the use of radiative hyperthermia systems. However, knowledge is limited as to how the frequency of the used radiative systems affects the immune phenotype of the treated tumor cells. By using our self-designed in vitro hyperthermia system, we compared cell death induction and expression of immune checkpoint molecules (ICM) on the tumor cell surface of murine B16 melanoma and human MDA-MB-231 and MCF-7 breast cancer cells following HT treatment with clinically relevant microwaves at 915 MHz or 2.45 GHz alone, radiotherapy (RT; 2 × 5 Gy or 5 × 2 Gy) alone or in combination (RHT). At 44 °C, HT alone was the dominant cell death inductor with inactivation rates of around 70% for B16, 45% for MDA-MB-231 and 35% for MCF-7 at 915 MHz and 80%, 60% and 50% at 2.45 GHz, respectively. Additional RT resulted in 5-15% higher levels of dead cells. The expression of ICM on tumor cells showed time-, treatment-, cell line- and frequency-dependent effects and was highest for RHT. Computer simulations of an exemplary spherical cell revealed frequency-dependent local energy absorption. The frequency of hyperthermia systems is a newly identified parameter that could also affect the immune phenotype of tumor cells and consequently the immunogenicity of tumors.

摘要

由放疗和免疫调节药物(如免疫检查点抑制剂)组成的多模式肿瘤治疗方案在临床上的应用越来越普遍。在这种情况下,肿瘤细胞的免疫表型对抗肿瘤免疫反应以及肿瘤微环境的组成有重大影响。进一步增强抗肿瘤免疫反应的一种有前景的方法是添加热疗(HT),即将肿瘤组织加热到39℃至45℃持续60分钟。一项关键技术是使用辐射热疗系统。然而,关于所用辐射系统的频率如何影响经治疗的肿瘤细胞的免疫表型,相关知识有限。通过使用我们自行设计的体外热疗系统,我们比较了在单独使用915MHz或2.45GHz的临床相关微波进行热疗(HT)、单独放疗(RT;2×5Gy或5×2Gy)或联合治疗(RHT)后,小鼠B16黑色素瘤细胞、人MDA-MB-231和MCF-7乳腺癌细胞的细胞死亡诱导情况以及肿瘤细胞表面免疫检查点分子(ICM)的表达。在44℃时,单独热疗是主要的细胞死亡诱导因素,在915MHz时,B16细胞的失活率约为70%,MDA-MB-231细胞为45%,MCF-7细胞为35%;在2.45GHz时,分别为80%、60%和50%。额外的放疗使死亡细胞水平提高了5 - 15%。肿瘤细胞上ICM的表达表现出时间、治疗、细胞系和频率依赖性效应,且在RHT时最高。对一个示例性球形细胞的计算机模拟显示了频率依赖性局部能量吸收。热疗系统的频率是一个新发现的参数,它也可能影响肿瘤细胞的免疫表型,进而影响肿瘤的免疫原性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f1a/8230049/d1b6b6ce03a0/cells-10-01436-g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f1a/8230049/418911f80220/cells-10-01436-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f1a/8230049/3e7011f0af1a/cells-10-01436-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f1a/8230049/c9292a44dc44/cells-10-01436-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f1a/8230049/c7248261644e/cells-10-01436-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f1a/8230049/068f3eafedac/cells-10-01436-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f1a/8230049/442e174a9a54/cells-10-01436-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f1a/8230049/75c1a79e2a5a/cells-10-01436-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f1a/8230049/3f767b5cd51f/cells-10-01436-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f1a/8230049/a272f1d10a4b/cells-10-01436-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f1a/8230049/1aeef0293b0c/cells-10-01436-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f1a/8230049/39ee17ed9a2a/cells-10-01436-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f1a/8230049/8b8a535a1542/cells-10-01436-g012a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f1a/8230049/d1b6b6ce03a0/cells-10-01436-g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f1a/8230049/418911f80220/cells-10-01436-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f1a/8230049/3e7011f0af1a/cells-10-01436-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f1a/8230049/c9292a44dc44/cells-10-01436-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f1a/8230049/c7248261644e/cells-10-01436-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f1a/8230049/068f3eafedac/cells-10-01436-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f1a/8230049/442e174a9a54/cells-10-01436-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f1a/8230049/75c1a79e2a5a/cells-10-01436-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f1a/8230049/3f767b5cd51f/cells-10-01436-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f1a/8230049/a272f1d10a4b/cells-10-01436-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f1a/8230049/1aeef0293b0c/cells-10-01436-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f1a/8230049/39ee17ed9a2a/cells-10-01436-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f1a/8230049/8b8a535a1542/cells-10-01436-g012a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f1a/8230049/d1b6b6ce03a0/cells-10-01436-g013.jpg

相似文献

1
In Vitro Examinations of Cell Death Induction and the Immune Phenotype of Cancer Cells Following Radiative-Based Hyperthermia with 915 MHz in Combination with Radiotherapy.基于915MHz辐射热疗联合放疗诱导癌细胞死亡及免疫表型的体外研究
Cells. 2021 Jun 8;10(6):1436. doi: 10.3390/cells10061436.
2
Broadband microwave spiral applicator (105-125 MHz) for examinations of hyperthermia-induced tumor cell death forms - first analyses with human breast cancer cells.宽带微波螺旋施源器(105-125MHz)用于检查热疗诱导的肿瘤细胞死亡形式- 首次用人乳腺癌细胞进行分析。
Int J Hyperthermia. 2023;40(1):2265590. doi: 10.1080/02656736.2023.2265590. Epub 2023 Oct 9.
3
Detailed analyses of the impact of multimodal cancer therapy with hyperthermia and radiotherapy on the immune phenotype of human glioblastoma cells.详细分析了热疗和放疗的多模态癌症疗法对人胶质母细胞瘤细胞免疫表型的影响。
Int J Hyperthermia. 2022;39(1):796-805. doi: 10.1080/02656736.2022.2080873.
4
The Effect of Hyperthermia and Radiotherapy Sequence on Cancer Cell Death and the Immune Phenotype of Breast Cancer Cells.热疗与放疗顺序对癌细胞死亡及乳腺癌细胞免疫表型的影响
Cancers (Basel). 2022 Apr 19;14(9):2050. doi: 10.3390/cancers14092050.
5
Differences of the Immune Phenotype of Breast Cancer Cells after Ex Vivo Hyperthermia by Warm-Water or Microwave Radiation in a Closed-Loop System Alone or in Combination with Radiotherapy.在闭环系统中,单独或联合放疗通过温水或微波辐射进行体外热疗后乳腺癌细胞免疫表型的差异
Cancers (Basel). 2020 Apr 27;12(5):1082. doi: 10.3390/cancers12051082.
6
The in vitro immunogenic potential of caspase-3 proficient breast cancer cells with basal low immunogenicity is increased by hypofractionated irradiation.低分割照射可增强具有基础低免疫原性的caspase-3功能正常的乳腺癌细胞的体外免疫原性。
Radiat Oncol. 2015 Sep 17;10:197. doi: 10.1186/s13014-015-0506-5.
7
Combination of ionising radiation with hyperthermia increases the immunogenic potential of B16-F10 melanoma cells in vitro and in vivo.电离辐射与热疗相结合可在体外和体内提高B16-F10黑色素瘤细胞的免疫原性潜力。
Int J Hyperthermia. 2016;32(1):23-30. doi: 10.3109/02656736.2015.1106011. Epub 2016 Jan 11.
8
Simultaneous superficial hyperthermia and external radiotherapy: report of thermal dosimetry and tolerance to treatment.同步浅表热疗与外照射放疗:热剂量测定及治疗耐受性报告
Int J Hyperthermia. 1999 Jul-Aug;15(4):251-66. doi: 10.1080/026567399285639.
9
Experimental approaches for the treatment of murine B16 melanomas of various sizes. I: Local injection of ethanol with a combination of interleukin-2 or microwaval hyperthermia for B16 melanomas with a size of less than 7 mm in diameter.治疗不同大小小鼠B16黑色素瘤的实验方法。I:直径小于7mm的B16黑色素瘤局部注射乙醇联合白细胞介素-2或微波热疗。
J Dermatol Sci. 1997 Aug;15(2):75-81. doi: 10.1016/s0923-1811(97)00595-1.
10
Trials of combined radiation and hyperthermia with various heating modalities in cancer therapy.癌症治疗中联合放疗与热疗以及各种加热方式的试验。
Radiat Med. 1984 Oct-Dec;2(4):260-4.

引用本文的文献

1
Pt-Au Nanoparticles in Combination with Near-Infrared-Based Hyperthermia Increase the Temperature and Impact on the Viability and Immune Phenotype of Human Hepatocellular Carcinoma Cells.铂-金纳米颗粒联合基于近红外的热疗可提高温度并影响人肝癌细胞的活力和免疫表型。
Int J Mol Sci. 2025 Feb 13;26(4):1574. doi: 10.3390/ijms26041574.
2
The Rationale for Combining Hypofractionated Radiation and Hyperthermia.超分割放疗与热疗联合应用的理论依据。
Cancers (Basel). 2024 Nov 22;16(23):3916. doi: 10.3390/cancers16233916.
3
Advances in Ferroptosis-Inducing Agents by Targeted Delivery System in Cancer Therapy.

本文引用的文献

1
Understanding PD-L1 Testing in Breast Cancer: A Practical Approach.了解乳腺癌中的程序性死亡配体1检测:一种实用方法。
Breast Care (Basel). 2020 Oct;15(5):481-490. doi: 10.1159/000510812. Epub 2020 Oct 6.
2
Advanced patient-specific hyperthermia treatment planning.先进的个体化热疗治疗计划。
Int J Hyperthermia. 2020;37(1):992-1007. doi: 10.1080/02656736.2020.1806361.
3
Lipid composition of the cancer cell membrane.癌细胞膜的脂质组成。
铁死亡诱导剂通过靶向传递系统在癌症治疗中的研究进展。
Int J Nanomedicine. 2024 Mar 5;19:2091-2112. doi: 10.2147/IJN.S448715. eCollection 2024.
4
A Novel Oncogenic Role of Disulfidptosis-related Gene SLC7A11 in Anti-tumor Immunotherapy Response to Human Cancers.二硫化物诱导细胞焦亡相关基因SLC7A11在人类癌症抗肿瘤免疫治疗反应中的新型致癌作用
Curr Cancer Drug Targets. 2024;24(8):846-866. doi: 10.2174/0115680096277818231229105732.
5
Combination Therapy of Radiation and Hyperthermia, Focusing on the Synergistic Anti-Cancer Effects and Research Trends.放疗与热疗联合治疗:聚焦协同抗癌效应及研究趋势
Antioxidants (Basel). 2023 Apr 13;12(4):924. doi: 10.3390/antiox12040924.
6
Cancer Immunology: From Molecular Mechanisms to Therapeutic Opportunities.癌症免疫学:从分子机制到治疗机会。
Cells. 2022 Jan 28;11(3):459. doi: 10.3390/cells11030459.
J Bioenerg Biomembr. 2020 Oct;52(5):321-342. doi: 10.1007/s10863-020-09846-4. Epub 2020 Jul 26.
4
Integrating Loco-Regional Hyperthermia Into the Current Oncology Practice: SWOT and TOWS Analyses.将局部区域热疗纳入当前肿瘤学实践:SWOT分析和TOWS分析
Front Oncol. 2020 Jun 12;10:819. doi: 10.3389/fonc.2020.00819. eCollection 2020.
5
Differences of the Immune Phenotype of Breast Cancer Cells after Ex Vivo Hyperthermia by Warm-Water or Microwave Radiation in a Closed-Loop System Alone or in Combination with Radiotherapy.在闭环系统中,单独或联合放疗通过温水或微波辐射进行体外热疗后乳腺癌细胞免疫表型的差异
Cancers (Basel). 2020 Apr 27;12(5):1082. doi: 10.3390/cancers12051082.
6
Recent technological advancements in radiofrequency- andmicrowave-mediated hyperthermia for enhancing drug delivery.射频和微波介导的热疗增强药物递送的最新技术进展。
Adv Drug Deliv Rev. 2020;163-164:3-18. doi: 10.1016/j.addr.2020.03.004. Epub 2020 Mar 27.
7
Radiotherapy-immunotherapy combinations - perspectives and challenges.放射治疗与免疫治疗联合——前景与挑战
Mol Oncol. 2020 Jul;14(7):1529-1537. doi: 10.1002/1878-0261.12658. Epub 2020 Mar 13.
8
Analysis of the immune status from peripheral whole blood with a single-tube multicolor flow cytometry assay.采用单管多色流式细胞术分析外周全血的免疫状态。
Methods Enzymol. 2020;632:389-415. doi: 10.1016/bs.mie.2019.03.003. Epub 2019 Apr 4.
9
Immune biological rationales for the design of combined radio- and immunotherapies.联合放化疗免疫治疗设计的免疫生物学原理。
Cancer Immunol Immunother. 2020 Feb;69(2):293-306. doi: 10.1007/s00262-019-02460-3. Epub 2020 Jan 18.
10
HVEM has a broader expression than PD-L1 and constitutes a negative prognostic marker and potential treatment target for melanoma.疱疹病毒侵入膜蛋白(HVEM)的表达比程序性死亡配体1(PD-L1)更广泛,是黑色素瘤的负性预后标志物和潜在治疗靶点。
Oncoimmunology. 2019 Sep 25;8(12):e1665976. doi: 10.1080/2162402X.2019.1665976. eCollection 2019.